Lupin Ltd (BOM:500257) Q3 2026 Earnings Call Highlights: Record Growth and Strategic Milestones

GuruFocus News

Sat, February 14, 2026 at 2:01 AM GMT+9 4 min read

In this article:

LUPIN.BO

-0.50%

This article first appeared on GuruFocus.

**Revenue:** INR7,168 crore, a 24% year-on-year growth.

**EBITDA:** INR2,210 crore, a 62% year-on-year increase, with a margin of 31.1%.

**EBITDA Margin:** 31.1%, up 681 basis points from the previous year.

**US Sales:** USD350 million, a 46% year-on-year growth.

**India Revenue Growth:** 5.6% year-on-year, with core prescription business growing 10.9%.

**Gross Margin:** 73.5%, up from 69.4% in the previous year.

**R&D Spend:** INR535 crore, 7.5% of sales.

**Net Cash:** INR2,879 crore as of December 31, 2025.

**Employee Benefit Expenses:** INR1,143 crore, a 16.1% year-on-year increase.

**Manufacturing and Other Expenses:** INR1,937 crore, a 14.2% year-on-year increase.

**Emerging Markets Growth:** 42% year-on-year, led by Brazil, Mexico, and Philippines.

**Other Developed Markets Growth:** 11% year-on-year.

**ETR (Effective Tax Rate):** Expected to be about 21% to 22% for the full year.

Warning! GuruFocus has detected 3 Warning Sign with BOM:532777.

Is BOM:500257 fairly valued? Test your thesis with our free DCF calculator.

Release Date: February 13, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Lupin Ltd (BOM:500257) reported its 14th consecutive quarter of year-on-year growth, with broad-based performance across regions including India, Europe, LatAm, and other emerging markets.

The US market recorded its highest sales ever, driven by new product launches such as Tolvaptan and generic Risperdal Consta, with CGT exclusivity.

Successful US FDA inspection of the Pune biologics facility and approval of pegfilgrastim, Lupin's first biosimilar for the US market, were significant milestones.

Emerging markets showed impressive growth, with Brazil growing 99% year-on-year in local currency, driven by successful commercialization of dapagliflozin.

Lupin's R&D spend was 7.5% of sales, reflecting a strong focus on complex and specialty platforms, with over 50 active products in the pipeline.

Negative Points

Technical difficulties during the earnings call led to communication issues, potentially affecting the clarity of the presentation.

Despite strong growth, the India business faced challenges with lower local tender sales impacting overall revenue growth.

The company anticipates a dip in Q4 margins due to higher R&D expenditure and lower PLI income.

The Mirabegron settlement involves a $90 million payout, which could impact profitability despite providing market certainty.

The competitive landscape in the US, particularly for biosimilars, remains challenging with potential new entrants and pricing pressures.

 






Story continues  

Q & A Highlights

Q: What are the future growth drivers for Lupin’s US business once Tolvaptan and Mirabegron start tapering off? A: Vinita Gupta, CEO, highlighted that Lupin plans multiple new product launches over the next few years, focusing on injectables, respiratory products, and biosimilars. The company has approvals for products like glucagon, Liraglutide, and Risperdal Consta, and is entering the biosimilars market with pegfilgrastim. The biosimilars and institutional business are expected to be significant growth drivers, alongside the development of 505(b)(2) products.

Q: Can you provide insights into the expected contribution of biosimilars like pegfilgrastim, ranibizumab, and aflibercept in the next few years? A: Vinita Gupta confirmed that these biosimilars have the potential to contribute significantly, with a combined potential of around $100 million in the next two to three years, assuming approvals come through as expected.

Q: How is Lupin utilizing AI across its operations? A: Ramesh Swaminathan, CFO, explained that Lupin is implementing AI across various functions, starting with sales and marketing, and extending to manufacturing, quality, finance, HR, and procurement. The company is working on consolidating data under one architecture and expects to implement pilot projects over the next 9 to 12 months.

Q: What is the strategy for the new semaglutide division in India? A: Nilesh Gupta, Managing Director, stated that the division will initially have about 200 medical representatives, with plans to scale as needed. The focus is on leveraging Lupin’s position as a large cardiometabolic player to capture prescription share, supported by a deep patient support program.

Q: How does the Mirabegron settlement impact Lupin’s financials and market share? A: Ramesh Swaminathan explained that the $15 million provision relates to past expenses, while $75 million is linked to future market presence. The settlement provides certainty and allows Lupin to maintain a 40% generic market share, with the potential to increase if it makes strategic sense.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Terms and Privacy Policy

Privacy Dashboard

More Info